Preferred Label : Tetravalent RNA-lipoplex Cancer Vaccine BNT111;
NCIt synonyms : Cancer Vaccine BNT111; RNA-lipoplex Vaccine BNT111; RNA-LPX BNT111; RNA(LIP) BNT111; Lipo-MERIT Vaccine;
NCIt definition : A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid
(RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the
four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the
human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein
phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity.
Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111,
the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen
and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the
cytoplasm and translated into the four tumor-associated proteins. The expressed proteins
are processed and the human leukocyte antigen (HLA)-peptide complexes are presented
to the immune system. This results in the production of various pro-inflammatory cytokines
and induces antigen-specific CD8 and CD4 T-cell responses against the four selected
MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.;
Molecule name : BNT-111; BNT 111;
Origin ID : C122396;
UMLS CUI : C5446294;
Semantic type(s)
- concept_is_in_subset
- has_target
